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a b s t r a c t 
Bumped kinase inhibitors (BKIs) are effective against a variety of apicomplexan parasites. Fifteen BKIs 
with promising in vitro efficacy against Neospora caninum tachyzoites, low cytotoxicity in mammalian 
cells, and no toxic effects in non-pregnant BALB/c mice were assessed in pregnant mice. Drugs were 
emulsified in corn oil and were applied by gavage for 5 days. Five BKIs did not affect pregnancy, five 
BKIs exhibited ~15–35% neonatal mortality and five compounds caused strong effects (infertility, abor- 
tion, stillbirth and pup mortality). Additionally, the impact of these compounds on zebrafish ( Danio rerio ) 
embryo development was assessed by exposing freshly fertilised eggs to 0.2–50 μM of BKIs and micro- 
scopic monitoring of embryo development in a blinded manner for 4 days. We propose an algorithm 
that includes quantification of malformations and embryo deaths, and established a scoring system that 
allows the calculation of an impact score (S i ) indicating at which concentrations BKIs visibly affect ze- 
brafish embryo development. Comparison of the two models showed that for nine compounds no clear 
correlation between S i and pregnancy outcome was observed. However, the three BKIs affecting zebrafish 
embryos only at high concentrations ( ≥40 μM) did not impair mouse pregnancy at all, and the three 
compounds that inhibited zebrafish embryo development already at 0.2 μM showed detrimental effects 
in the pregnancy model. Thus, the zebrafish embryo development test has limited predictive value to 
foresee pregnancy outcome in BKI-treated mice. We conclude that maternal health-related factors such 
as cardiovascular, pharmacokinetic and/or bioavailability properties also contribute to BKI–pregnancy ef- 
fects. 
© 2020 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 














Neospora caninum and Toxoplasma gondii are obligate intracel-
ular protozoan parasites belonging to the phylum Apicomplexa.
hey have a worldwide distribution and are found in many dif-∗ Corresponding author. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) erent species, infecting different cell types and tissues. Toxoplasma
nd Neospora undergo three distinct infective stages: rapidly pro-
iferating tachyzoites that cause acute disease and are responsi-
le for vertical transmission during pregnancy; slowly proliferating
radyzoites that are responsible for chronic infection, which are
nclosed in tissue cysts that are orally infective; and sporulated
ocysts containing sporozoites, the end product of a sexual cycle
hat takes place within canine ( Neospora ) or feline ( Toxoplasma )under the CC BY-NC-ND license. 
























































































































intestinal tissue, which are shed with the faeces and ingested by
intermediate hosts [ 1 , 2 ]. 
Primary oral infection through oocysts or tissue cysts from both
species during pregnancy can result in exogenous transplacental
infection of the fetus, with grave consequences. In cattle persis-
tently infected with N. caninum , endogenous transplacental infec-
tion upon recrudescence and reactivation of dormant bradyzoites
during pregnancy represents the most abundant mode of fetal in-
fection. Thus, N. caninum causes bovine abortion and inflicts sig-
nificant economic losses up to US $1.3 billion according to data
derived from 10 countries [3] . N. caninum infection has also been
reported in many other species including sheep and goats, but
not in humans. T. gondii poses highly important veterinary, med-
ical, economic and public-health problems as it infects all warm-
blooded animals, but it also has a very high zoonotic potential
[1] . In humans, congenital toxoplasmosis causes fetal malforma-
tions and abortion, and recrudescence of latent infection or new
infections in immunosuppressed individuals can cause acute toxo-
plasmosis with potentially lethal outcome [4] . 
Calcium-dependent protein kinase 1 (CDPK1) has emerged as
an important drug target in apicomplexans [5] . Homologues of
CDPK1 are not present in mammals but appear to have descended
from the plant kingdom [6] . CDPK1 is crucially involved in sig-
nalling events that lead to host cell invasion and egress [ 7 , 8 ].
A promising group of compounds are bumped kinase inhibitors
(BKIs), which target CDPK1. CDPK1 is structurally similar in many
apicomplexans [5] . The high degree of efficacy and specificity of
BKIs in apicomplexans relative to mammalian kinases is due to dif-
ferences in the topology of a hydrophobic pocket within the ATP-
binding site that is, in part, determined by the size of their re-
spective gatekeeper residues [9] . BKIs have proven in vitro activity
against Babesia bovis [6] and Besnoitia besnoiti [10] as well as in
vitro and in vivo against Cryptosporidium spp. [11–17] , Cystoisospora
suis [18] , T. gondii [19–21] and N. caninum [21–23] . 
Despite promising efficacy, some BKIs have shown toxicity
in vivo . For instance, BKI-1294 inhibited the human ether-à-
go-go-related gene (hERG) in vitro [24] . The 5-aminopyrazole-4-
carboxamide compound BKI-1517 did not inhibit hERG in vitro but
caused a significant change in mean arterial pressure when dosed
in rats [17] . However, in pregnant BALB/c mice infected with N.
caninum , BKI-1294 had a profound impact on vertical transmis-
sion and offspring mortality [25] . Similarly, BKI-1294 impacted on
T. gondii oocyst infection in pregnant CD1 mice, achieving 100%
offspring survival and significant inhibition of vertical transmission
[20] . Two other BKIs (BKI-1517 and BKI-1553) also inhibited N. can-
inum proliferation in vitro and were highly efficacious and safe in
non-pregnant mice, but were shown to interfere with pregnancy
outcomes in N. caninum -infected mice [23] . Thus, potential preg-
nancy interference is an important issue for the development of
drugs designed to inhibit vertical transmission. This interference
can be assessed by performing a small pilot study with a few non-
infected pregnant mice that are treated with the drug during early-
to-mid pregnancy [26] . 
Zebrafish ( Danio rerio ) have been increasingly used for the eval-
uation of agrochemical agents and toxicity assessments of pharma-
ceuticals [ 27 , 28 ]. Zebrafish embryos are a valuable model for toxi-
city testing and have numerous advantages, including low mainte-
nance cost, small size, transparency of the embryo and rapid devel-
opment, all of which render investigations time and cost effective
[ 27 , 29 , 30 ]. The Organisation for Economic Co-operation and Devel-
opment (OECD) has designed a fish embryo toxicity test using the
zebrafish model. This assay is used to determine the lethal effects
of chemicals on embryonic stages of fish as an alternative method
to acute toxicity tests with juvenile and adult fish [31] . 
In the present study, a zebrafish embryo development test was
established to assess the toxicity of 15 distinct BKIs with respecto early embryonal death and induction of malformations and to
nvestigate the predictive value of the BKI–zebrafish test in relation
o pregnancy interference in mice. We show here that the zebrafish
mbryo model can be a cost-effective screen of novel drugs that
an contribute to the reduction of higher-order animals to be used
n such studies. 
. Materials and methods 
.1. Tissue culture, biochemicals and compounds 
Cell culture media were purchased from Gibco/BRL (Zürich,
witzerland) and biochemical reagents were obtained from Sigma
St Louis, MO, USA). BKIs ( Table 1 ) were obtained from the Center
or Emerging and Re-emerging Infectious Diseases (CERID) of the
niversity of Washington (Seattle, WA, USA). For in vitro studies
nd use in zebrafish assays, BKIs were stored as 50 mM stock so-
utions in dimethyl sulfoxide (DMSO) at –20 °C. For application in
ice, BKIs were directly suspended in corn oil and were adminis-
rated by oral gavage. 
.2. Cytotoxicity assessment in human foreskin fibroblasts (HFF) and 
n human hepatocyte (HepG2) and lymphocyte (CRL-8155) cell lines 
HFF were cultured in Dulbecco’s modified Eagle (DMEM) with
henol red supplemented with 10% fetal calf serum (FCS) and 50
/mL penicillin and were maintained as previously described [32] .
o measure cytotoxicity, HFF monolayers were grown in 96-well
lates and were exposed to medium containing serial dilutions
f BKIs (0.0 0 09–20 μM). Controls included cultures treated with
MSO as well as HFF in medium alone. Following culture at 37
C in 5% CO 2 for 3 days, medium was discarded and cells were
ashed once with phosphate-buffered saline (PBS). Cytotoxicity
as measured by alamarBlue R © assay as described previously [32] .
epG2 (hepatocyte) or CRL-8155 (lymphocyte) cells were cultured
s previously described [33] with minor modifications. HepG2 cells
ere grown in DMEM/F12 medium plus l -glutamine and 15 mM
EPES, and CRL-8155 cells were grown in RPMI-1640 medium plus
0 mM HEPES, 1 mM sodium-pyruvate and l -glutamine, both me-
ia supplemented with 10% FCS. Cells were grown in the presence
f varying concentrations of inhibitor, starting at 40 μM or 80 μM
epending on the solubility, and then serial three-fold dilutions
ere performed. Cultures were maintained for 48 h at 37 °C and
% CO 2 in 96-well flat-bottom plates. Growth was quantified using
lamarBlue R © (Life Technologies, USA). Percent growth inhibition
CC 50 = drug concentration causing 50% cytotoxicity) by test com-
ounds was determined based on cultures incubated with DMSO
negative control) and quinacrine (positive control) (0% and 100%
rowth inhibition, respectively) [33] . All assays were performed in
riplicate. 
.3. In vitro efficacy against N. caninum 
A transgenic N. caninum strain constitutively expressing β-
alactosidase (Nc- βgal) [25] was maintained by serial passages in
FF. HFF monolayers cultured in 96-well plates were infected with
0 3 Nc- βgal tachyzoites per well in the presence of serial dilutions
f BKIs (0.0164–2 μM). After 3 days of culture in the presence of
he drugs, wells were washed once with 200 μL of PBS and pro-
iferation was assessed as described previously [25] . EC 50 values
half-maximal drug concentration that inhibits tachyzoite prolifer-
tion by 50%) were calculated after the logit-log transformation of
elative growth and subsequent regression analysis by use of the
orresponding software tool contained in the Excel software pack-
ge (Microsoft Corp., Seattle, WA, USA). 
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Table 1 
Structures of bumped kinase inhibitors (BKIs) investigated in this study and their corresponding effects on N. caninum proliferation 
and cytotoxicity in human foreskin fibroblasts (HFF) and in human hepatocyte (HepG2) and lymphocyte (CRL-8155) cell lines 
BKI Structure Proliferation EC 50 ( μM) 
N. caninum 
Cytotoxicity CC 50 ( μM) 
HepG2 CRL-8155 HFF 
1294 0.040 + > 40 > 40 > 20 
1369 0.035 > 80 > 80 > 20 
1770 0.144 > 80 > 80 > 20 
1750 0.076 > 40 > 40 > 20 
1772 0.112 > 80 > 80 > 20 
1553 0.180 ++ > 40 39.5 > 20 
1757 0.142 > 80 > 80 > 20 
1660 0.164 > 40 > 40 > 20 
1713 0.098 > 40 > 40 > 20 
1774 0.066 > 80 nd > 20 
1517 0.269 > 40 > 40 > 20 
1796 0.067 > 80 > 80 > 20 
1751 0.117 > 40 > 40 > 20 
( continued on next page ) 
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Table 1 ( continued ) 
BKI Structure Proliferation EC 50 ( μM) 
N. caninum 
Cytotoxicity CC 50 ( μM) 
HepG2 CRL-8155 HFF 
1649 0.071 > 40 > 40 > 20 
1748 0.068 > 40 > 40 > 20 
EC 50 , half-maximal drug concentration that inhibits tachyzoite proliferation by 50%; CC 50 , drug concentration causing 50% cytotoxi- 
city. 















































































2.4. Ethics statement 
All protocols involving animals were approved by the Animal
Welfare Committee of the Canton of Bern (Switzerland). Animals
were handled in strict accordance with practices to minimise suf-
fering. All mice were maintained in a common room under con-
trolled temperature and a 14/10 h light/dark cycle. All procedures
were carried out according to the guidelines set by the animal wel-
fare legislation of the Swiss Veterinary Office. 
2.5. Assessment of bumped kinase inhibitor interference in murine 
pregnancy 
Eight-week-old BALB/c mice (98 females and 49 males) were
purchased from Charles River Laboratories (Sulzfeld, Germany). Fe-
male mice were randomly allocated to 16 experimental groups (6–
7 mice/group; 2–3 females/cage; 3 cages/group), with 15 groups
undergoing BKI treatments and 1 group receiving placebo (corn
oil). Females were oestrus-synchronised by the Whitten effect
[22] and were mated for 3 nights (1 male per 2 females), after
which males were removed from the cages. All BKIs (see Table 1 )
were suspended in corn oil and were administered by oral gavage
(50 mg/kg/day in 100 μL) from Day 9 to Day 13 post-mating as de-
scribed previously for BKI-1294 treatment [ 20 , 22 , 23 ]. The only ex-
ception was BKI-1796, which was administered at 25 mg/kg body
weight on Days 1, 3 and 5. The placebo group received 100 μL
of corn oil only per day for 5 days. Weight measurements of each
mouse were carried out every 3–4 days to detect pregnant animals,
and animals were inspected daily to detect potential abortions,
which would also cause rapid weight loss. On Day 18 post-mating,
pregnant females were separated into individual cages, where they
gave birth on Days 20–22. Live and stillborn pups were counted
and dead pups were removed. Data on fertility, litter size, pup
mortality and the clinical status of the dams were recorded. Dams
and live pups were monitored at least 2 weeks after birth to rule
out possible late adverse effects. At the end of the experiment,
pups were euthanised by decapitation. Adult mice were euthanised
in a euthanasia chamber using isoflurane and CO 2 . 
2.6. Assessment of bumped kinase inhibitor interference in zebrafish 
embryo development 
The overall setup of the assay is shown in Fig. 1 A. At 3 h post-
fertilisation (hpf), zebrafish eggs were transferred into a Petri dish
(Sarstedt Inc., Nümbrecht, Germany) containing E3 medium (5 mM
NaCl, 0.17 mM KCl, 0.33 mM CaCl 2 and 0.33 mM Mg SO 4 , buffered
to pH 7.5 using sodium bicarbonate)/osmosis water containing the
tested drug concentration. From there, viable eggs were transferrednto the respective 24-well plate (Sarstedt), with one egg/well in 1
L of the same solution. The plate maps are shown in Fig. 1 B. Each
4-well plate contained 20 wells with the test solution at a given
oncentration and 4 wells without drug as internal controls (iC).
he negative control plate was comprised of 20 wells containing
 mL of E3 medium/osmosis water. The solvent control plate was
omprised of 20 wells containing 1 mL of E3 medium containing
.01% DMSO. The positive control plate was comprised of 20 wells
ontaining 1 mL of 3,4-dichloroaniline (4 g/L), which is an estab-
ished and widely used control substance in zebrafish embryo tox-
city tests [34] . The BKI plates were composed of 20 wells contain-
ng 1 mL/well of the respective BKI. All BKIs were assessed at six to
ight concentrations ranging from 0.2–50 μM. All plates were cov-
red with sealing foil and the embryos were maintained at 28 °C.
est solution was replaced every 24 h with fresh solution. Embryos
ere viewed and malformations or viability changes were assessed
n a blinded manner using a Nikon eclipse TS100 light microscope
t 10 × magnification at 24, 48, 72 and 96 hpf, with plates kept on
 heating pad at 26 °C during observation and medium changes.
he parameters that were monitored and scored are detailed in
ig. 2 . At 96 hpf, all embryos were euthanised by immersion in
 solution of pre-cooled 3-101 aminobenzoic acid ethyl ester (100
g/L; MS222; Argent Chemical Laboratories, Redmond, WA, USA)
nd placing them at –20 °C for 24 h. 
.7. Proposed algorithm for the assessment of drug impact on 
ebrafish embryo development 
The formula for calculating the impact score (S i ) of a given drug
r control solution is shown in Fig. 3 . A total of 20 eggs (N e = 20)
ere microscopically assessed for each concentration of a given
ompound or the respective negative or solvent controls. In each
ssay, a score of –1 was assigned for death during the 96 hpf,
hereas each malformation seen on a hatched embryo received
 score of –0.5, including non-hatched embryos at 96 hpf. Thus,
he score for a given assay (S assay ) was calculated by subtracting
he scores for dead embryos (N d ) and the scores for malforma-
ions (N m divided by two) from N e (see Fig. 3 ). The mean control
core (S mean ) was determined by calculating the mean of the nega-
ive control score (S neg ) and the solvent control score (S DMSO ). The
verall impact score for a given drug concentration (S i ) was finally
alculated by subtracting S mean from the S assay achieved with the
est dilution. We propose that a negative S i indicates interference,
hereas an S i of ≥0 implies no interference in early embryo de-
elopment. 
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Fig. 1. Setup of the zebrafish embryo development assay. (A) Freshly fertilised eggs are transferred into a Petri dish containing the test solution, viable eggs are selected 
microscopically, and 24 eggs containing viable embryos are transferred into a 24-well plate (1 egg/well). In the 24-well plate, 20 wells contain 1 mL of bumped kinase 
inhibitor (BKI) solution at a defined concentration (T) and 4 wells serve as internal control (iC). (B) 24-well plate setup. T, BKI test concentration; nC, negative control (E3 
medium/osmosis water); iC, internal control (E3 medium/osmosis water); sC, solvent control (DMSO); pC, positive control (4 g/L of 3,4-dichloroaniline in water) (adapted 














































p  . Results 
.1. Effects of bumped kinase inhibitors on N. caninum tachyzoites 
nd mammalian cells cultured in vitro 
The structures of the BKIs assessed in this work are depicted in
able 1 . When added concomitantly to infection of HFF monolayers
y N. caninum , they inhibited proliferation of tachyzoites with EC 50 
alues ranging between 0.035 μM and 0.180 μM ( Table 1 ; Sup-
lementary Fig. S1). Compounds were not toxic to HFF host cell
onolayers at a concentration of up to 20 μM, and no cytotox-
city was seen up to 40 μM or 80 μM in CRL-8155 and HepG2
ells when assessed by alamarBlue R © assay, except for BKI-1553,
hich impaired the viability of CRL-8155 cells to 50% at 39.5 μM
 Table 1 ). 
.2. Effects of bumped kinase inhibitors on mouse pregnancy and 
ffspring viability 
The results on pregnancy interference of 15 BKIs in pregnant
ice are shown in Table 2 . In the placebo group, four of six mice
ndergoing mating became pregnant, with a total of 19 pups born
live and no deaths observed during the follow-up period of 14
ays. None of the 15 BKIs assessed in these experiments notably
ffected non-pregnant mice (data not shown). In pregnant mice,ve compounds did not interfere with pregnancy outcome, whilst
he others showed moderate to dramatic adverse effects in terms
f offspring survival. 
Treatment with BKI-1294 resulted in four of six pregnant mice
iving birth to an overall number of 27 pups, of which all survived
ntil 14 days post-partum. Similar results were obtained with BKI-
369. Relative to the placebo control, BKI-1750 resulted in the ex-
ct same fertility and number of pups. BKI-1770 and BKI-1772 were
nly slightly lower for fertility and this difference was not signifi-
ant compared with the controls. 
In cases where interference in pregnancy was noted, pups were
ither resorbed, aborted or born dead, or neonatal mortality took
lace within 2 days after birth. No further deaths occurred dur-
ng the 12 days follow-up. Pup mortality rates between ~15–35%
ere noted in experimental groups treated with BKI-1553, BKI-
660, BKI-1713, BKI-1757 and BKI-1774. 
Other compounds interfered with pregnancy much more
everely, such as BKI-1517. Abortion or a high degree of offspring
ortality was also noted for BKI-1748. In the group treated with
KI-1751, two of six dams were supposedly pregnant as assessed
y weight, but no pups were found on the day of supposed
irth, and one pregnant mouse was found dead on Day 21 post-
ating. In the group treated with BKI-1796, which was assessed
t 25 mg/kg on Days 1, 3 and 5, four of six mice were sup-
osed pregnant according to their weight gain, but no viable pups
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Fig. 2. Normal development of zebrafish embryo and bumped kinase inhibitor (BKI)-induced malformations observed during the test period. (A–E) Normal zebrafish embryo 
development at 0.75, 24, 48, 72 and 96 h post-fertilisation (hpf). (F–N) Representative images of embryonal alterations observed during BKI exposure: (F) coagulated embryo 
(observed with BKI-1796, 24 hpf/50 μM); (G) absence of eye bud ( ∗) and tail non-detachment ( → ) (BKI-1796, 24 hpf/50 μM); (H) pericardial oedema ( → ) (BKI-1517, 24 
hpf/50 μM); (M and I) body deformation ( → ) and pericardial oedema ( ∗) (BKI-1757, 24 hpf/5 μM); (J) tail curvature ( → ) and half-hatched embryo ( ∗) (BKI 1517, 24 hpf/20 
μM); (K) curved tail ( → ) and pericardial oedema ( ∗) (BKI-1796, 24 hpf/40 μM); (L) back curvature (scoliosis) ( → ) (BKI-1750, 24 hpf/10 μM); (M) head deformation ( → ) 
(BKI-1796, 24 hpf/10 μM); and (N) curved tail ( → ) (BKI-1796, 24 hpf/10 μM). 
Table 2 
Results of the mouse pregnancy interference tests and zebrafish embryo development interfer- 
ence tests using a panel of 15 bumped kinase inhibitors (BKIs). With the exception of BKI-1796, 
drugs were applied by daily oral gavage at a dose of 50 mg/kg/day during 5 days from Days 
7–11 of pregnancy. Fertilised zebrafish eggs were exposed to six to eight different drug con- 
centrations (0.2–50 μM) until 96 h post-fertilisation. Grey background highlights those com- 
pounds for which the two models show corresponding results 
Treatment BALB/c mice Zebrafish embryos 




negative S i ( μM) 
Placebo 4/6 19/4 0/19 n.a. 
3,4-Dichloroaniline n.a. n.a. n.a. > 50 
1294 4/6 27/4 0/27 40 
1369 5/6 31/5 0/31 40 
1770 3/6 17/3 0/17 > 50 
1750 4/6 19/4 0/19 5 
1772 ∗∗ 3/6 17/3 0/17 2 
1553 3/6 16/3 6/16 5 
1660 3/6 14/3 3/14 5 
1713 4/6 20/4 4/20 20 
1774 ∗∗ 4/6 22/4 3/22 20 
1757 4/6 15/4 3/15 0.2 
1517 ∗2/7 0/2 – 0.2 
1796 a ∗4/6 0/4 – 0.2 
1751 ∗2/6 0/2 – 5 
1649 4/6 0/4 – 10 
1748 3/6 5/3 1/5 20 
S i , impact score. 
a BKI-1796 was applied at 25 mg/kg on Days 1, 3 and 5. 
∗ Dams were determined to be pregnant by weight gain in the last trimester of pregnancy. 
They lost their offspring shortly before or during birth. 
∗∗ Indicates compounds where precipitation was noted visually in water at concentrations of 
≥20 μM. 
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Fig. 3. Proposed algorithm for the zebrafish embryo development assay score cal- 
culation. Every compound concentration receives a score based on the negative 
control and the solvent control. S neg = negative control score (no compound, no 
DMSO); S DMSO = solvent control score (no compound, 0.01% DMSO); S assay , as- 
say score (score for each compound concentration); S mean = control mean score; 
S i = impact score; N e = number of embryos introduced per test item (20 per com- 
pound and concentration); N d = number of dead embryos after 96 hpf (score –1 for 
each dead embryo); N m = number of embryonal malformations observed after 96 
hpf (score –0.5 for each malformation, including non-hatched embryos at 96 hpf). 









































































































C  ere born and blood stains were found in the cage. The fact that
hese animals lost up to 5 g within 2 days indicates they had
borted. 
.3. Effects of bumped kinase inhibitors on early zebrafish embryo 
evelopment 
Assessment of the effects of BKIs on zebrafish embryo develop-
ent was based on daily microscopic inspection of 20 individual
ertilised eggs for each drug and respective concentration cultured
4–96 hpf, either in the presence or absence of compounds. This
isual assessment was blinded with respect to treatment. Typical
orphological features of normally developing zebrafish embryos
ithin the 96 hpf are shown in Fig. 2 A–E. No differences could be
etected between the negative control group and the DMSO sol-
ent control group. Typical examples of the different types of drug-
nduced malformations rated in our studies are shown in Fig. 2 F–N.
In cases where toxicity was observed, the effects were mostly
ose-dependent. The lowest concentrations causing adverse effects
n early zebrafish embryo development for each compound are
hown in Table 2 . A detailed account of the number of malfor-
ations, deaths and impact scores obtained in the test groups are
rovided in Supplementary Table S1, and for selected compounds
he results are also shown as graphs, with S i values plotted against
rug concentrations in Supplementary Fig. S2. In addition, Supple-
entary Fig. S3 shows graphs of the toxicity of selected BKIs ver-
us time (hpf). Notably, only three compounds (BKI-1294, BKI-1369
nd BKI-1770) exhibited very low embryo toxicity, with negative
mpact scores assigned to them at 40 μM and/or above 50 μM.
hese three BKIs also do not interfere in pregnancy outcome in the
ouse model (see above). Nine BKIs interfered in early embryo de-
elopment at concentrations ranging from 2 μM to 20 μM. Three
KIs (BKI-1757, BKI-1517 and BKI-1796) were very embryo-toxic at
he lowest concentration of 0.2 μM. BKI-1757 partially interfered
n pregnancy outcome (3 neonatal deaths of 15 pups), whilst the
ther two exhibited more dramatic effects, with no viable offspring
orn. 
. Discussion 
The BKIs assessed in this study all exhibited promising in vitro
ctivity against N. caninum tachyzoites, with EC 50 values in the
ower submicromolar range, with no viability impairment of testedammalian cells. The lack of host cell impairment by these BKIs is
n important prerequisite to advance studies in small animal mod-
ls. Based on their in vitro efficacy and specificity, these drugs are
romising leads as N. caninum therapeutics and for the treatment
f other diseases caused by apicomplexan parasites. 
Vertical transmission is the most important mode of N. caninum
nfection. Thus, compounds to be applied against neosporosis could
e used in the treatment of pregnant animals when immunity is
ownmodulated to prevent exogenous transplacental transmission
nd to limit endogenous transplacental transmission in chronically
nfected animals due to recrudescence. Compounds could also be
pplied to treat congenitally infected newborns to prevent the for-
ation of tissue cysts [3] . Thus, besides reaching therapeutic lev-
ls in the central nervous system, drugs should be able to cross
he placenta in order to eliminate infection in fetal tissues without
nducing harmful maternal physiological changes or exerting ter-
togenic effects, which most likely occur during the initial phases
f embryo development owing to rapid cell proliferation and in-
reased metabolic activity [35] . 
Whilst neosporosis is a disease that is mainly important in ru-
inants, economic considerations demand that studies on the ba-
ic features of N. caninum infection, potential vaccine candidates
nd novel antiparasitic drugs be carried out in small laboratory an-
mals such as mice. Regardless of the drawbacks of using mouse
odels, even though they do not fully reflect N. caninum infection
n cattle, they do provide initial information on the protective ef-
ects of potential treatments [2] . 
The 15 BKIs assessed in this study can be divided into three
istinct groups. Group 1 contains five BKIs that did not induce ad-
erse effects in pregnant mice. Three of these (BKI-1294, BKI-1369
nd BKI-1770) affected zebrafish embryo development only at high
oncentrations ( ≥40 μM), whilst the other two (BKI-1750 and BKI-
772) exhibited zebrafish embryo toxicity already at 5 μM and 2
M, respectively. Group 2 is comprised of five BKIs that exhibit
oderate interference in pregnancy, with ~15–35% of offspring loss
ithin the first few days after birth. Zebrafish embryo develop-
ent was impaired at 0.2 μM by BKI-1557 and at 5 μM or 20 μM
y the others. Group 3 consisted of five BKIs that displayed fetal
oss during pregnancy, abortion, stillbirth and neonatal mortality,
ith very few offspring still alive after birth. Zebrafish embryo de-
elopment was impaired already at 0.2 μM by two of these BKIs;
he others exhibited effects on zebrafish embryos at concentrations
etween 5 μM and 20 μM. 
This limited data set illustrates two points: (i) the three com-
ounds that exhibited interference in zebrafish embryo develop-
ent at 0.2 μM also had a negative impact on pregnancy outcome
s reflected by the reduced offspring survival, indicating that em-
ryo toxicity at 0.2 μM is predictive for pregnancy failure in this
ouse model; and (ii) the lack of microscopically visible embryo
oxicity does not imply that there will be a successful pregnancy
utcome, suggesting that other determinants of maternal physi-
logy, possibly affected by drug treatments, are important. How-
ver, it is also possible that visual inspection of morphological de-
elopment cannot fully explain all mechanisms of embryotoxicity.
hus, more studies need to be carried out to corroborate these
ndings. 
BKI-1294, BKI-1369 and BKI-1770 are group 1 compounds not
ffecting zebrafish development at high concentrations. BKI-1294
as previously shown to be safe and efficacious in non-pregnant
nd pregnant BALB/c mice infected with N. caninum tachyzoites
 22 , 25 ] and was also highly efficacious in non-pregnant T. gondii -
nfected mice [19] and in pregnant mice infected with T. gondii
ocysts [20] . However, the latter model was based on CD1 outbred
ice, and T. gondii infected and drug-treated CD1 mice gave birth
o significantly lower numbers of pups compared with non-treated
D1 mice. This implied that interference in pregnancy could be an























































































































issue dependent on the mouse strain, in addition to other factors.
Recently, BKI-1294 treatment was applied in pregnant sheep exper-
imentally infected with T. gondii oocysts where it was partially ef-
ficacious against T. gondii infection, and no adverse effects of drug
treatment were noted in this small ruminant model [36] . BKI-1369
and BKI-1770 are lead compounds for the treatment of diarrhoea
caused by cryptosporidiosis in calves [ 15 , 17 ]. In addition, excellent
efficacy of BKI-1369 was demonstrated against C. suis infection in
piglets [18] and in a pig model of acute diarrhoea caused by Cryp-
tosporidium hominis [16] . 
BKI-1553, a compound with low hERG inhibitory activity [24] ,
also exhibited considerable effects on pregnancy outcome when
applied at 50 mg/kg, but it had been shown earlier that this ef-
fect could be alleviated by a three times treatment at 20 mg/kg
every second day, which reduced neonatal mortality but still main-
tained considerable antiparasitic activity in N. caninum -infected
pregnant mice [23] . BKI-1553 is highly active against T. gondii in
vitro , crosses the blood–brain barrier in mice when orally applied,
and reduces the T. gondii burden in brain, lungs and liver [24] . The
safety and efficacy of BKI-1553 was also demonstrated in pregnant
sheep experimentally infected with N. caninum tachyzoites. Subcu-
taneous application resulted in reduced fetal mortality by 50% [21] .
N. caninum was abundantly found in placental tissues, but para-
site detection in fetal brain tissue decreased from 94% in the in-
fected/untreated group to 69–71% in the treated groups. 
Three BKIs exhibited clear embryo toxicity at the lowest dose of
0.2 μM and also induced moderate to severe disturbances in preg-
nancy outcome when applied at 50 mg/kg for 5 days. Among them,
BKI-1517 has been previously investigated in N. caninum -infected
pregnant mice. At 50 mg/kg, 100% neonatal mortality was observed
and this was confirmed in the current study. At 20 mg/kg, BKI-
1517 significantly decreased the rate of vertical transmission and
increased offspring survival [23] . BKI-1517 also displayed promising
efficacy against Cryptosporidium spp . [ 12 , 14 ]. In the experiments
of the current study, the compound did not show toxicity against
mammalian cells. However, it exhibited high toxicity at all concen-
trations in the zebrafish assay, which explains its detrimental ef-
fects in pregnant mice. 
The reasons for the toxicity of some of the BKIs is not known.
BKIs act as ATP competitive inhibitors of CDPK1 [37] , but inter-
actions with other kinases exhibiting bulkier gatekeeper residues
cannot be ruled out. One of the possible off-targets is PKD3, an-
other serine/threonine kinase that is associated with the mitotic
apparatus, including spindle, centrosome, mid-body formation, and
development of cardiac and skeletal muscle tissue [ 38 , 39 ]. The
dual-specificity kinase MEK1 is another kinase potentially targeted
by BKIs. It plays an activating role in the ERK/MAPK cascade, which
is involved in cell fate determination and regulation of cell prolifer-
ation and differentiation. MEK1 gene disruption in embryonic stem
cells resulted in death of embryos after 10 days of gestation [40] .
These results suggest that both kinases are important for the de-
veloping fetus, and compounds that inhibit their normal function
may result in teratogenic effects. 
Whilst the mouse pregnancy safety model plays an important
role in drug development, especially for BKIs targeting vertical
transmission of pathogens, it cannot be maintained as a routine
screening platform owing to the extensive use of animals, the high
amount of compound required, time-consuming procedures and
the costs involved. In addition, there are physiological differences
between mouse placenta and the placenta of humans and other
mammalian species, with anticipated consequences regarding fetal
drug susceptibility issues [41] . In this respect, the zebrafish em-
bryo development model could serve an important purpose for
the identification of BKIs with teratogenic potential, with higher
throughput, lower costs and more rapid results, and could poten-
tially serve to eliminate embryo-toxic compounds early on. Onemportant limitation is that feasibility is restricted to water-soluble
ompounds. In the current study, precipitates were observed in
ests with BKI-1772 and BKI-1774 at ≥20 μM, and respective re-
ults at 20 μM are inconclusive. In addition, it only makes sense
o carry out such studies at therapeutic concentrations. Thus, it is
elpful to know the pharmacokinetics of each compound and then
hoose the concentrations accordingly. Despite these potential pit-
alls, the zebrafish model can serve as an important pre-screening
ool that could contribute to the 3Rs (replacement, reduction and
efinement) and allow more efficient testing of BKIs as well as
ther antiparasitic drugs to be applied during pregnancy. In addi-
ion, future studies with a much larger data set will show how our
roposed algorithm for the calculation of a drug impact score (S i )
n zebrafish embryo development will perform in predicting drug
nterference in pregnancy in mice. 
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